46 -3 (77) 2025 - Shamsiyeva M.A. - CLINICAL AND LABORATORY CHARACTERISTICS OF CHRONIC HEPATITIS C

CLINICAL AND LABORATORY CHARACTERISTICS OF CHRONIC HEPATITIS C

Shamsiyeva M.A. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

In terms of fibrosis and disease progression, the relationship between HCV and steatosis is unclear. HCV genotype 3 is clearly associated with steatosis. In some patients, steatosis may be associated with the development of fibrosis. The mechanisms underlying this association are unknown. This article describes and discusses the main and clinical-laboratory and instrumental aspects of the relationship between the development of steatosis and fibrosis and the response to treatment in patients with chronic hepatitis C.

Keywords: chronic hepatitis C, hepatic steatosis, hepatotropic virus, hepatocytes, fatty acid, fibrosis tissue.

First page

247

Last page

249

For citation:Shamsiyeva M.A. - CLINICAL AND LABORATORY CHARACTERISTICS OF CHRONIC HEPATITIS C //New Day in Medicine 3(77)2025 247-249 https://https://newdayworldmedicine.com/en/new_day_medicine/3-77-2025

List of References

  1. Alberti A, Boccato S, Vario A, Benvegnu L. Therapy of acute hepatitis C. // Hepatology. 2002;36(5 Suppl 1):195-200.
  2. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. // N Engl J Med. 1999;341:556-562.
  3. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. // Hepatology. 2002;36(5 Suppl 1):179-184.
  4. Ibrokhimovna M.M. (2024). Improvement of Primary Prophylaxis and Treatment of Spontaneous Bacterial Peritonitis Complicated in Virus Etiology Liver Cirrhosis. Journal of Intellectual Property and Human Rights, 2024;3(4):19-25. Retrieved from http://journals.academiczone.net/index.php/jiphr/article/view/2506
  5. Oblokulov Abdurashid Rakhimovich Mukhammadieva Musharraf Ibrokhimovna Sanokulova Sitora Avazovna Khadieva Dora Isakovna. (2023). Clinical and laboratory features of spontaneous bacterial peritonitis in patients with viral liver cirrhosis. // Journal of Advanced Zoology, 2023;44(S2):3744–3750. Retrieved from http://www.jazindia.com/index.php/jaz/article/view/1716
  6. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology. 2002;36(5 Suppl 1):121-127.
  7. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. // Gastroenterology. 2006;130:231-264.
  8. El-Zayadi AR, Attia M, Barakat EM, et al. Response of hepatitis C genotype-4 naive patients to 24 weeks of Peginterferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study. // Am J Gastroenterol. 2005;100:2447-2452.
  9. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. // Gastroenterology. 1997;112:463-472.
  10. Mukhammadieva M.I. (2023). Вирус этиологияли жигар циррози беморларида спонтан бактериал перитонит билан асоратланишнинг профилактикаси ва давосини такомиллаштириш // Oriental Renaissance: Innovative, educational, natural and social sciences. 2023; 947-953 pp.
  11. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis // C. Nature. 2005;436:967-972.
  12. Fried MW. Side effects of therapy of hepatitis C and their management. // Hepatology. 2002;36(5 Suppl 1):237-244.

    file

    download